Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Mangalam Drugs & Organics Ltd. ( (IN:MANGALAM) ) just unveiled an update.
Mangalam Drugs & Organics Limited’s board met on 6 February 2026 and approved several key changes in its leadership structure and governance. The board accepted the resignation of independent director Rukmesh P. Dhandhania with effect from 16 January 2026, appointed Jeevan M. Dalvi as Chief Financial Officer effective 6 February 2026, and cleared the re-appointment of Dr. Praveen Saxena as an independent director for a second five-year term starting 21 March 2026, subject to shareholder approval by special resolution. These decisions signal an ongoing refresh of the company’s financial leadership and a continuation of experienced independent oversight on the board, developments that are likely to be closely watched by investors for their implications on corporate governance and financial management.
More about Mangalam Drugs & Organics Ltd.
Mangalam Drugs & Organics Limited is an Indian pharmaceutical and chemicals company engaged in manufacturing active pharmaceutical ingredients and intermediates, operating production facilities in Vapi, Gujarat, with its registered office in Mumbai. The company’s shares are listed on both BSE and the National Stock Exchange of India under the symbol MANGALAM, positioning it within the listed mid-cap pharma/chemicals universe.
Average Trading Volume: 58,419
Technical Sentiment Signal: Sell
Current Market Cap: 571.6M INR
Learn more about MANGALAM stock on TipRanks’ Stock Analysis page.